Assessment of ECMO in Acute Myocardial Infarction Cardiogenic Shock

Recruiting N/A Interventional Study
Acute Myocardial Infarction Cardiogenic Shock
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
400 (estimated)
Sponsor
Assistance Publique - Hôpitaux de Paris · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Data from case series and large retrospective trials suggest that the early treatment of cardiogenic shock AMI patients with the association of VA-ECMO and IABP may significantly decrease mortality, which is still unacceptably high nowadays (40-50% at 30 days). An important benefit for the patients randomized to the ECMO arm is expected and the risk-to-benefit ratio is expected to be in favor of …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Cardiogenic shock complicating acute myocardial infarction (STEMI or NSTEMI) * Revascularization by PCI for acute myocardial infarction has been performed or is planned in the following 60 minutes * Systolic blood pressure \<90 mmHg for \>30 min or catecholamine support requir…
Contacts

Alain COMBES, MD, PhD

01.42.16.38.16

alain.combes@aphp.fr

CONTACT

Gilles MONTALESCOT, MD, PhD

01.42.16.30.07

gilles.montalescot@aphp.fr

CONTACT